Edition:
United States

Sarepta Therapeutics Inc (SRPT.O)

SRPT.O on Nasdaq

46.73USD
20 Sep 2017
Change (% chg)

$0.96 (+2.10%)
Prev Close
$45.77
Open
$45.75
Day's High
$46.86
Day's Low
$45.26
Volume
1,588,030
Avg. Vol
2,320,706
52-wk High
$63.73
52-wk Low
$26.26

Select another date:

Wed, Sep 6 2017

Sarepta's shares jump on new DMD drug's promising trial results

Sarepta Therapeutics Inc's shares surged on Wednesday after the results of a trial on its drug to treat a fatal muscle-wasting disease showed it had the potential to be more effective than the company's approved drug for the same disease.

UPDATE 1-Sarepta's shares jump on new DMD drug's promising trial results

Sept 6 Sarepta Therapeutics Inc's shares surged on Wednesday after the results of a trial on its drug to treat a fatal muscle-wasting disease showed it had the potential to be more effective than the company's approved drug for the same disease.

Sarepta shares rise as new DMD drug succeeds early stage trial

Sept 6 Sarepta Therapeutics Inc's shares jumped about 15 percent on Wednesday after the company's drug to treat patients with a form of a fatal muscle-wasting disease met the main goal of an early-stage trial.

BRIEF-Sarepta Therapeutics reports positive results in study

* Sarepta Therapeutics announces positive results in its study evaluating gene expression, dystrophin production, and dystrophin localization in patients with duchenne muscular dystrophy (DMD) amenable to skipping exon 53 treated with golodirsen (SRP-4053)

Sarepta Therapeutics defeats investor lawsuit on appeal

A federal appeals court on Tuesday upheld the dismissal of a lawsuit accusing Sarepta Therapeutics Inc of misleading investors about the likelihood that its flagship treatment for a rare muscle disorder would gain regulatory approval.

BRIEF-Paulson & Co takes share stake in Apple, dissolves share stake in Sarepta, Biogen

* Ups share stake in T-Mobile US Inc by 46.1 percent to 6.1 million shares - SEC filing

BRIEF-Sarepta Therapeutics announces pricing of $325 mln public offering of common stock

* Sarepta Therapeutics announces pricing of $325 million public offering of common stock

BRIEF-Sarepta Therapeutics announces proposed $250 mln public offering of common stock

* Sarepta Therapeutics announces proposed $250 million public offering of common stock

Sarepta surges after stellar DMD drug powers on

Shares of Sarepta Therapeutics Inc soared 25 percent on Thursday after the U.S. drugmaker reported much better-than-expected quarterly sales of its Duchenne muscular dystrophy (DMD) drug as the launch of the treatment steamrolls on.

UPDATE 1-Sarepta surges after stellar DMD drug powers on

July 20 Shares of Sarepta Therapeutics Inc soared 25 percent on Thursday after the U.S. drugmaker reported much better-than-expected quarterly sales of its Duchenne muscular dystrophy (DMD) drug as the launch of the treatment steamrolls on.

Select another date: